Conduct of Research Programs. MTEM (directly or through its Affiliates or subcontractors) shall use Commercially Reasonable Efforts to perform the activities under each Research Plan in accordance with the terms of such Research Plan (including the Research Budget and timeframes therein) and the terms of this Agreement, and will perform such activities in a professional manner and in accordance with all Applicable Laws. ​. For clarity, except as set forth in [Section 2.2.4, MTEM]M] shall not be obligated to procure materials or incur other out-of-pocket costs or undertake any work with respect to a Research Program if such out-of-pocket costs or the cost of such work would exceed the Research Budget set forth in the applicable Research Plan, as the same may be updated or amended in accordance with [Section 2.2.3].

Conduct of Research. Each Party shall use ​ Efforts to carry out the activities assigned to it in the Research Plans in accordance with the timelines set forth in such plans. Each Party shall conduct such activities in good scientific manner, and in compliance with all applicable Laws. Each Party shall keep the other Party reasonably informed as to the progress of the conduct of the Research Plans through meetings of the JRC.

Conduct of Research. Each Party shall use commercially reasonable efforts to perform all research activities under this Agreement in compliance with all applicable Laws (including GMP, GLP, GVP and GCP).

Conduct of Research. Each Party shall use its Commercially Reasonable Efforts to perform the activities assigned to such Party in each Research Plan and to achieve the timeline(s) set forth in such Research Plan. [[Adimab:Organization]]’s performance obligations under each Research Program shall be contingent upon iTeos providing the iTeos Materials, if any, set forth in the applicable Research Plan. Such iTeos Materials are expected to include Target antigen of suitable quality for performance of the Research Program. [[Adimab:Organization]]’s obligations with regard to the performance of a particular Research Program shall be subject to the iTeos Materials passing [[Adimab:Organization]]’s quality control standards. [[Adimab:Organization]]’s obligations with regard to the performance of a particular Research Program shall expire at the end of the applicable Research Term. [[Adimab:Organization]] shall have the right to use Third Parties in the performance of its obligations hereunder.

Conduct of Research. Each Party shall use Commercially Reasonable Efforts to carry out the activities assigned to it under the Research Plans in accordance with the timeline therefor contemplated by the applicable Research Plan and shall conduct such activities in good scientific manner, in compliance with all applicable Laws in all material respects, including where applicable, cGMP, GLP and GCP.

Conduct of Research Activities. LogicBio will conduct the activities allocated to LogicBio under the Pompe and Fabry Research Plan in accordance with the terms thereof and within the timelines set forth therein.

Conduct of Research. Each Party shall conduct the activities assigned to it under the Research Plan. Each Party shall conduct such activities in accordance with the timelines in the Research Plan, in good scientific manner and in compliance with all applicable Laws.

Conduct of the Research. CRISPR will, and will require its Affiliates and Subcontractors to, comply with all Applicable Laws in its and their conduct of the activities under the [[Unknown Identifier]] Guide Research Plan, including where appropriate cGMP and GLP (or similar standards). CRISPR will dedicate such number of FTEs as is reasonably required to perform the activities under the [[Unknown Identifier]] Guide Research Plan. For the avoidance of doubt, the [[Unknown Identifier]] Guide Research shall not be conducted in animals.

Conduct of Research. Each Party shall use Diligent Efforts to carry out the Research activities assigned to it in the Research Plan and shall conduct such activities in good scientific manner, and in compliance with all applicable Laws. Each Party shall keep the other Party reasonably informed as to its progress in the conduct of the Research Plan through meetings of the JRC. At least [ * ] Business Days before each JRC meeting, each Party shall submit to the JRC a written summary of its Research activities since its prior report. All [ * ] under the Research Plan will be [ * ], provided that neither Party will be required to [ * ] where it reasonably believes that [ * ].

Conduct of Research. Each Party will use its Commercially Reasonable Efforts to perform the activities assigned to such Party in a Research Plan and to achieve the timeline(s) set forth in such Research Plan. [[Adimab:Organization]]’s obligation to start performance of a Research Program hereunder will be subject to # the availability of reagents of sufficient quality and quantity, and # the availability of [[Adimab:Organization]] researchers to perform such Research Program, and [[Adimab:Organization]] will provide [[Alector:Organization]] with reasonable notice as to the availability of its researchers to start performance of its obligations under a Research Plan at the time of negotiation of such Research Plan. [[Alector:Organization]] Materials are expected to include Target antigen of suitable quality for performance of the Research Program and such [[Alector:Organization]] Materials must pass [[Adimab:Organization]]’s quality control standards prior to commencing the Research Program. [[Adimab:Organization]]’s performance obligations under a Research Program will expire at the end of the Research Term for such Research Program. [[Adimab:Organization]] will have the right to use Third Parties in the performance of its obligations hereunder. [[Adimab:Organization]] will have the right to use Third Party Contractors in the performance of its obligations hereunder; provided, however, that: # [[Adimab:Organization]] provides written notice to [[Alector:Organization]] identifying such Third Party Contractor and [[Alector:Organization]] agrees to [[Adimab:Organization]]’s use of such Third Party Contractor; # any such subcontract will be subject to the relevant terms and conditions of this Agreement; # [[Adimab:Organization]] will enter into agreements with its Third Party Contractors that contain confidentiality terms no less stringent than those set forth in Article 6 (CONFIDENTIALITY; PUBLICITY) hereof and assignment of inventions provisions consistent with the requirements of this Agreement; and # no such subcontracting will relieve [[Adimab:Organization]] of its obligations hereunder.